Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2668610 | 1.00 | KDM4E (0.51) | KDM4EKMT2ASMN1; SMN2ALDH1A1FOXM1 | |
| SCHEMBL14899739 | 0.93 | FOXM1 (0.54) | KDM4EKMT2ASMN1; SMN2ALDH1A1FOXM1 | |
| SCHEMBL2668594 | 0.93 | FOXM1 (0.54) | KDM4EKMT2ASMN1; SMN2ALDH1A1FOXM1 | |
| Hydrochloric Acid SCHEMBL7297661 | 0.91 | KMT2A (0.56) | KDM4EKMT2ASMN1; SMN2ALDH1A1FOXM1 | |
| SCHEMBL3252860 | 0.84 | FOXM1 (0.61) | KDM4EKMT2ASMN1; SMN2ALDH1A1FOXM1 | |
| Hydrochloric Acid SCHEMBL4159801 | 0.83 | FOXM1 (0.59) | KDM4EKMT2ASMN1; SMN2ALDH1A1FOXM1 | |
| SCHEMBL2659080 | 0.82 | KDM4E (0.57) | KDM4EKMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL9071936 | 0.82 | KDM4E (0.57) | KDM4EKMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL14117439 | 0.81 | GRIN2B (0.67) | ALDH1A1GRIN2BGRIN1SIGMAR1OPRM1 | |
| SCHEMBL2661157 | 0.80 | GRIN2B (0.68) | ALDH1A1GRIN2BGRIN1SIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586614-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-11-19 | — | — | US | disclosed |
| EP-2377856-A1 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2011-10-19 | — | — | EP | disclosed |
| US-20110077234-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-7884210-B2 | {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-02-08 | — | — | US | disclosed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-1904467-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105482-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | KDM4E 637/4885KMT2A 1200/4885SMN1; SMN2 2536/4885 |
| US-20110077234-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | KDM4E 637/4885KMT2A 1200/4885SMN1; SMN2 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.